AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 10764172
Drug: Intravenous 10
RxNorm normalized name: fat emulsion, intravenous 10% intravenous emulsion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous 10 mg morphine (Group IV)
Trial: 10764172
Drug: Inhalation anesthesia
RxNorm normalized name: Gelato Anesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhalation anesthesia alone (Group C)
Trial: 8844444
Drug: VX-366 (1,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VX-366 (1, 7, 14 or 28 grams or approximately 14, 100, 200 or 400 mg/kg)
Trial: 8844444
Drug: VX-366 (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VX-366 (100 to 150 mg/kg)
Trial: 6190318
Drug: simultaneous radio-chemotherapy
RxNorm normalized name: Valerianae radix
DrugBank: Valerian (DB13196)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: simultaneous radio-chemotherapy
Trial: 23558909
Drug: Goal-directed therapy
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Goal-directed therapy (GDT) with continuous monitoring of stroke volume variation (SVV) and stroke volume (SV) using FloTrac/Vigileo, receiving 1,589 ml of colloids during surgery.
Trial: 23558909
Drug: Goal-directed therapy
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Goal-directed therapy (GDT) with continuous monitoring of stroke volume variation (SVV) and stroke volume (SV) using FloTrac/Vigileo, SVV decreased from 9.0 to 8.0 % during surgery.
Trial: 23558909
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (CON) receiving 927 ml of colloids during surgery.
Trial: 23778198
Drug: Multicomponent cognitive
RxNorm normalized name: meningococcus B, multicomponent vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multicomponent cognitive behavioral group intervention (8 weekly sessions + 1 booster session)
Trial: 14700554
Drug: Growth hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth hormone (GH) replacement for 12 months
Trial: 2964253
Drug: Amlodipine (2.5-10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amlodipine (2.5-10 mg daily, titrated at 2 weekly intervals for 8 weeks)
Trial: 2964253
Drug: Amlodipine (various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amlodipine (various doses)
Trial: 23975134
Drug: Hydroxychloroquine sulfate
RxNorm normalized name: Hydroxychloroquine Sulfate
DrugBank: Hydroxychloroquine (DB01611)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hydroxychloroquine sulfate tablets
Trial: 12535040
Drug: Propofol infusion
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol infusion anaesthesia (3 mg x kg‐1 induction, 20, 15 and 10 mg x kg‐1 x h‐1 maintenance)
Trial: 12535040
Drug: Thiopenthal induction
RxNorm normalized name: thiopental Injectable Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thiopenthal induction (5 mg x kg‐1) followed by halothane maintenance (2-3%)
Trial: 10377733
Drug: Interferon (IFN)
RxNorm normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon (IFN) therapy for chronic HBV hepatitis: 5 MU thrice weekly for 6 months
Trial: 10377733
Drug: Interferon (IFN)
RxNorm normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon (IFN) therapy for chronic hepatitis C: protocols changed over time from 3 x 3 MU for 6 months to 3 x 3 MU for 12 months, including combination with ribavirin
Trial: 9193433
Drug: Early ramipril
RxNorm normalized name: Ramipril
DrugBank: Ramipril (DB00178)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early ramipril (10 mg)
Trial: 9193433
Drug: Delayed ramipril
RxNorm normalized name: Ramipril
DrugBank: Ramipril (DB00178)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Delayed ramipril (10 mg, day 14)
Trial: 3959968
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg buprenorphine
Trial: 3959968
Drug: 4 mg
RxNorm normalized name: lutein 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg buprenorphine
Trial: 3959968
Drug: Urine assay
RxNorm normalized name: Urin DS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Urine assay for opiate drugs
Trial: 11279974
Drug: Histamine (0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Histamine (0.1 to 1 ng, subcutaneous administration, twice a week for 12 weeks)
Trial: 11279974
Drug: Placebo (subcutaneous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (subcutaneous administration, twice a week for 12 weeks)
Trial: 1578306
Drug: Daily corticosteroid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily corticosteroid regimen
Trial: 1578306
Drug: Daily corticosteroid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily corticosteroid regimen (after switching to alternate-day therapy)
Trial: 1578306
Drug: Alternate-day corticosteroid
RxNorm normalized name: Alternaria alternata
DrugBank: Alternaria alternata (DB10424)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alternate-day corticosteroid therapy (continued from the outset)
Trial: 2859648
Drug: Blockade of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blockade of histamine receptors with Fenistil plus Tagamet
Trial: 27020487
Drug: Prophylactic intravenous
RxNorm normalized name: polylactic acid-polyglycolic acid copolymer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic intravenous ephedrine 10mg (Group E)
Trial: 23702697
Drug: IVIG (1-2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IVIG (1-2 g/kg, over 2 days)
Trial: 22884767
Drug: Insulin glargine
RxNorm normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Insulin glargine (starting dose, 4 U)
Trial: 16044784
Drug: Evidence-based medicine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Evidence-based medicine (EBM) methods of comparison
Trial: 16044784
Drug: Cognition-based medicine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognition-based medicine (CBM)
Trial: 7043753
Drug: CMF +
RxNorm normalized name: Cyclophosphamide, Methotrexate, and Fluorouracil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CMF + MER (immunotherapy with methanol extract residue of BCG)
Trial: 29784470
Drug: MenACWY-TT (single-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MenACWY-TT (single-dose at 15-18 months)
Trial: 29784470
Drug: Routine childhood
RxNorm normalized name: Peace Out Acne Hero Routine KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine childhood vaccines (PHiD-CV and DTPa-IPV/Hib)
Trial: 29784470
Drug: All groups
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All groups (MenACWY-TT and routine vaccines)
Trial: 22903909
Drug: Group music
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group music therapy for 10 weeks
Trial: 12088814
Drug: Intravenous midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous midazolam 0.1 mg/kg followed by 7% sevoflurane with 50% N(2)O
Trial: 9569075
Drug: Intramuscular methylprednisolone
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intramuscular methylprednisolone acetate (i.m. MP) 120 mg 3-weekly
Trial: 9569075
Drug: Oral prednisolone
RxNorm normalized name: prednisolone Oral Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral prednisolone (OP) initial dose 15 mg, gradually tapering
Trial: 9569075
Drug: Intramuscular methylprednisolone
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intramuscular methylprednisolone acetate (i.m. MP)
Trial: 8547555
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg of intrapleural morphine (IPM group)
Trial: 8547555
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg of intravenous morphine (IVM group)
Trial: 523421
Drug: Ethambutol (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ethambutol (25 mg/kg daily) for 8 days in healthy subjects
Trial: 31896529
Drug: Antidepressant medications
RxNorm normalized name: ANTIDEPRESSANTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antidepressant medications (ADM)
Trial: 31896529
Drug: Both Antidepressant
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both Antidepressant medications (ADM) and Cognitive therapy (CT)
Trial: 30611343
Drug: Intravenous infusion
RxNorm normalized name: intravenous infusion pump accessory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion of 15 mg/kg of tranexamic acid (TXA)
Trial: 28278717
Drug: Directly observed
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Directly observed therapy (DOT) with intermittent, high-dose Vitamin D3
Trial: 25443996
Drug: Usual care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual care (n=42): psychotherapy, pharmaceutical interventions, and group therapy.
Trial: 19760753
Drug: Phlebotomies to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phlebotomies to obtain a ferritin level <50 ng/mL followed by pegylated‐Interferon alpha2b + ribavirin
Trial: 19760753
Drug: Phlebotomies and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phlebotomies and antiviral therapy
Trial: 9389947
Drug: Clindamycin hydrochloride
RxNorm normalized name: Clindamycin Hydrochloride
DrugBank: Clindamycin (DB01190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clindamycin hydrochloride capsules, 150 mg by mouth four times daily for 7 consecutive days.
Trial: 9389947
Drug: Placebo (partner
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (partner treatment).
Trial: 9389947
Drug: Clindamycin hydrochloride
RxNorm normalized name: Clindamycin Hydrochloride
DrugBank: Clindamycin (DB01190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clindamycin hydrochloride capsules, 150 mg by mouth four times daily for 7 consecutive days (among women cured by the first week's visit).
Trial: 9389947
Drug: Placebo (partner
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (partner treatment, among women cured by the first week's visit).
Trial: 7707159
Drug: Twice a
RxNorm normalized name: Pataday Twice A Day Relief
DrugBank: Olopatadine (DB00768)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Twice a day slow-release nifedipine
Trial: 29100903
Drug: Antibiotics (n=34)
RxNorm normalized name: N-(3,4-Dimethoxycinnamoyl)anthranilic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotics (n=34)
Trial: 29100903
Drug: Antibiotics (n=32)
RxNorm normalized name: N-Vanillylnonamide
DrugBank: Nonivamide (DB11324)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotics (n=32)
Trial: 23876062
Drug: Capecitabine (1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capecitabine (1000 mg/m2 orally BID, days 1 to 14 of 21) in combination with Sorafenib (600 mg/day orally BID, days 1 to 21)
Trial: 18180683
Drug: Cyclosporine 0.05%
RxNorm normalized name: CYCLOSPORINE 0.05% (PF) EMULSION,OPH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclosporine 0.05% ophthalmic emulsion (Restasis; Allergan, Inc.) used twice daily
Trial: 18180683
Drug: Placebo group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo group receiving rewetting drops (Refresh Preservative Free Artificial Tears; Allergan, Inc.) used twice daily
Trial: 11729030
Drug: 3 g/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 g/day ethyl eicosapentaenoic acid (EPA)
Trial: 8269914
Drug: Thiamine (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thiamine (50 mg/day)
Trial: 8269914
Drug: Placebo (two
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (two tablets per day)
Trial: 2957348
Drug: Amoxycillin 1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxycillin 1.0 g intramuscularly
Trial: 30033356
Drug: Lorcaserin 10mg,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lorcaserin 10mg, twice a day for 24 weeks
Trial: 22658268
Drug: Osteopathic Manipulative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Osteopathic Manipulative Treatment (OMT) + Specific Exercises (SE)
Trial: 7829604
Drug: GH treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GH treatment (0.2 IU/kg.week for 6 months)
Trial: 334471
Drug: 600 mg
RxNorm normalized name: mesna 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg phenylbutazone
Trial: 334471
Drug: 2.1 g
RxNorm normalized name: GLYCERIN 2.1 g RECTAL SUPPOSITORY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.1 g aspirin
Trial: 31104056
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D 2,000 IU tablet every other day for 12 weeks
Trial: 15060509
Drug: lopinavir (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lopinavir (400 mg twice daily) and ritonavir (100 mg twice daily)
Trial: 15060509
Drug: amprenavir (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: amprenavir (600 mg twice daily) plus ritonavir (100 mg twice daily)
Trial: 15060509
Drug: lopinavir (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lopinavir (400 mg twice daily) and ritonavir (100 mg twice daily) plus additional ritonavir (100 mg twice daily)
Trial: 15060509
Drug: amprenavir (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: amprenavir (600 mg twice daily) plus ritonavir (200 mg twice daily)
Trial: 8154531
Drug: Lodoxamide 0.1%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lodoxamide 0.1% ophthalmic solution
Trial: 31180819
Drug: Adjuvant chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant chemotherapy with oral tegafur-uracil
Trial: 25707402
Drug: Lowest 1,25(OH)2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lowest 1,25(OH)2 D levels (8.70 to 51.60 pg/mL)
Trial: 19622108
Drug: Rectal diclofenac
RxNorm normalized name: diclofenac Rectal Suppository
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rectal diclofenac 100 mg (Group 1, n = 19)
Trial: 19622108
Drug: Placebo suppository
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo suppository (Group 2, n = 18)
Trial: 19622108
Drug: Rectal diclofenac
RxNorm normalized name: diclofenac Rectal Suppository
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rectal diclofenac (Group 1)
Trial: 17387026
Drug: Paracetamol 1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paracetamol 1000 mg three times daily
Trial: 15596757
Drug: Pregabalin (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pregabalin (300 mg/day and 600 mg/day)
Trial: 9404176
Drug: nalbuphine 0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nalbuphine 0.1 mg.kg‐1
Trial: 9404176
Drug: pethidine 1
RxNorm normalized name: Pethidine
DrugBank: Meperidine (DB00454)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: pethidine 1 mg.kg‐1
Trial: 8424396
Drug: Mitomycin plus
RxNorm normalized name: Mitomycin
DrugBank: Mitomycin (DB00305)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mitomycin plus high-dose medroxyprogesterone acetate (MMPA)
Trial: 31257067
Drug: Tailored therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tailored therapy (PPI, amoxicillin, and clarithromycin for 7 days; PPI, amoxicillin, and levofloxacin for 10 days; PPI, amoxicillin, and metronidazole for 14 days)
Trial: 31257067
Drug: Empirical therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Empirical therapy (PPI, amoxicillin, and clarithromycin for 7 days)
Trial: 26509763
Drug: Gatifloxacin 0.3%
RxNorm normalized name: GATIFLOXACIN 0.3% SOLN,OPH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gatifloxacin 0.3% (monotherapy)
Trial: 26509763
Drug: Fortified cefazolin
RxNorm normalized name: Cefazolin
DrugBank: Cefazolin (DB01327)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fortified cefazolin sodium 5% and tobramycin sulfate 1.3% (combination therapy)
Trial: 25327732
Drug: YAZ (drospirenone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: YAZ (drospirenone 3 mg and ethinylestradiol 20 µg)
Trial: 21038654
Drug: Shenyanning (SYN)
RxNorm normalized name: Gel-Syn
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Shenyanning (SYN) Decoction, one dose per day for 1 year
Trial: 21038654
Drug: Losartan (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Losartan (50 mg per day for 1 year)
Trial: 2646418
Drug: 7% tetrapotassium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7% tetrapotassium peroxydiphosphate (PDP) solution administered as a subgingival irrigant
Trial: 2646418
Drug: Placebo rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo rinse similar to the test solution, but without PDP
Trial: 2646418
Drug: 7% tetrapotassium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7% tetrapotassium peroxydiphosphate (PDP) solution
Trial: 788739
Drug: Phenylbutazone 50
RxNorm normalized name: Phenylbutazone
DrugBank: Phenylbutazone (DB00812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Phenylbutazone 50 mg/day
Trial: 788739
Drug: Phenylbutazone 100
RxNorm normalized name: phenylbutazone 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phenylbutazone 100 mg/day
Trial: 788739
Drug: Phenylbutazone 200
RxNorm normalized name: phenylbutazone 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phenylbutazone 200 mg/day
Trial: 913873
Drug: Phenylbutazone 400
RxNorm normalized name: Phenylbutazone
DrugBank: Phenylbutazone (DB00812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Phenylbutazone 400 mg/day
Trial: 913873
Drug: Phenylbutazone (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phenylbutazone (all doses)
Trial: 913873
Drug: Phenylbutazone 50
RxNorm normalized name: Phenylbutazone
DrugBank: Phenylbutazone (DB00812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Phenylbutazone 50 and 100 mg/day
Trial: 913873
Drug: Phenylbutazone 200
RxNorm normalized name: phenylbutazone 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phenylbutazone 200 and 400 mg/day
Trial: 31704518
Drug: Anodal transcranial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anodal transcranial direct current stimulation (tDCS) over the left inferior frontal gyrus combined with written naming/spelling therapy
Trial: 31704518
Drug: Sham tDCS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham tDCS over the left inferior frontal gyrus combined with written naming/spelling therapy
Trial: 27876449
Drug: Paraffin therapy
RxNorm normalized name: Paraffin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paraffin therapy (n = 27)
Trial: 27876449
Drug: Placebo therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo therapy (n = 25)
Trial: 23939631
Drug: Sotatercept 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sotatercept 1 mg/kg
Trial: 21291564
Drug: Decentralised and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Decentralised and non-specialised standard psychiatric treatment
Trial: 19524906
Drug: 200mg of
RxNorm normalized name: Oil of peppermint
DrugBank: Peppermint oil (DB11198)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200mg of oral iron tablets 3 times a day for 4 weeks
Trial: 11158764
Drug: Trovafloxacin (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trovafloxacin (200 mg)
Trial: 8509683
Drug: diclofenac sodium
RxNorm normalized name: Diclofenac Sodium
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: diclofenac sodium 0.1% eye drops (Voltaren Ophthalmic)
Trial: 20437564
Drug: Monthly gadolinium-enhanced
RxNorm normalized name: gadolinium
DrugBank: Gadolinium (DB12091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monthly gadolinium-enhanced T1-weighted (Gd-T1w) imaging
Trial: 16165718
Drug: Oral ferrous
RxNorm normalized name: ferrous fumarate Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral ferrous fumarate (Neo‐fer) 120 mg orally once daily
Trial: 16165718
Drug: Intravenous iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous iron sucrose (Venofer) 200 mg intravenously 3 times during a period of 14 days
Trial: 10809863
Drug: Odorants with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Odorants with a sedative effect
Trial: 519476
Drug: Praziquantel 30
RxNorm normalized name: praziquantel 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Praziquantel 30 mg/kg
Trial: 2005563
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of lidocaine, epinephrine, hyaluronidase with bupivacaine
Trial: 6519165
Drug: Lasix (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lasix (40 mg)
Trial: 6519165
Drug: Furix (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Furix (40 mg)
Trial: 29458928
Drug: Vitamin D3
RxNorm normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D3 (28,000 IU weekly for 8 weeks)
Trial: 24881917
Drug: Methotrexate 1
RxNorm normalized name: methotrexate 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methotrexate 1 g/m(2) over 24 hours with intrathecal injection (MTX1 arm)
Trial: 24881917
Drug: Methotrexate 3
RxNorm normalized name: methotrexate 37.5 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methotrexate 3 g/m(2) over 3 hours without intrathecal injection (MTX3 arm)
Trial: 24881917
Drug: Overall treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall treatment in Japan (both MTX1 and MTX3 arms)